Myasthenia Gravis Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Cholinesterase Inhibitors, Corticosteroids, Immunosuppressants, IVIg, Monoclonal Antibody), By Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Others), and Region 2020-2031

Myasthenia Gravis Market was valued at approximately US$ 1,380 million in 2024 and is projected to reach about US$ 2,050 million by 2031, expanding at a CAGR of 5.8% during the forecast period (2025–2031). Moreover, the U.S. Myasthenia Gravis Market is expected to grow significantly, reaching an estimated value of US$ 890 million by 2031, driven by increasing prevalence, early diagnosis, and the launch of targeted biologic therapies.

The myasthenia gravis market is during radical transformation as immunotherapy, precision medicine, and rare disease expertise combine to revolutionize patient treatment. As an autoimmune, chronic neuromuscular disorder, Myasthenia Gravis (MG) poses special therapeutic challenges, such as changing weakness in muscles and disrupted neuromuscular transmission. Traditionally underpenetrated, this orphan disease category is now being targeted by pharmaceutical innovators driven by regulatory incentives and future biologics pipelines. With advancements in diagnostic technology and treatment paradigms transitioning away from wide-spread immunosuppression to targeted biologics, the marketplace is shifting toward more targeted and sustained disease management strategies, particularly in moderate to severe MG cases with refractory symptoms to traditional therapies.

Greater healthcare infrastructure, greater clinical trial activity, and growing access to neuromuscular specialists are also driving diagnosis and treatment volumes globally. At the same time, rare disease groups and patient groups have been a driving force in raising awareness and securing favorable reimbursement, especially in Europe and North America. The business success of the monoclonal antibody medications of recent history, coupled with extremely promising late-stage products against complement pathways and neonatal Fc receptors (FcRn), is a strong pipeline that is going to reshape the MG therapeutic horizon. With ever-improving neurological treatment paradigms being embraced by emerging economies, the Myasthenia Gravis market globally is anticipated to see steady, innovation-driven growth.

Facts & Figures

• Adjusted prevalence in the United States in 2021 was put at 316.4 cases per million, corresponding to an estimated 82,715 affected American adults. Incidence among Medicaid-insured individuals was slightly lower, at 49.7 new cases per million person-years.
• A 2021 meta-analysis of 29 more recent studies (2007–2019) reported greater global variability, MG incidence varying from 0.15 to 61.33 per million person-years with geographic and reporting method variability. A further 2021 report put the incidence of MG at between 4.1 and 30 per million person-years, cementing the condition yet again as a rare but valued autoimmune disease.   

Key Developments

• In May 2025, the U.S. FDA has approved Imaavy (nipocalimab), the first-of-class treatment directed at the underlying cause of gMG in adults and children aged 12+, providing long-lasting relief for about 100,000 patients in the United States.
• In August 2024, MyHealthTeam introduced MGteam in August 2024, a specialized digital platform offering community-based support, disease information, and medically vetted content to empower individuals living with myasthenia gravis through collective experience and well-informed care choices.
• In May 2024, Telitacicept, which was developed by RemeGen, was the first biologic in China to be approved to target BLyS and APRIL for generalized myasthenia gravis (gMG). It was approved by the NMPA and marks a milestone in local innovation and is likely to revolutionize treatment regimens in China.

Myasthenia Gravis Market Segmentation

Based on the drug class

• Cholinesterase Inhibitors
• Corticosteroids
• Immunosuppressants
• IVIg
• Monoclonal Antibodies

Monoclonal antibodies are currently the most revolutionary drug class in the Myasthenia Gravis treatment model, particularly for patients with moderate to severe generalized MG that is resistant to standard treatments. These biologic agents, including complement inhibitors and FcRn antagonists, provide targeted immune modulation with reduction of pathogenic autoantibodies at less systemic immunosuppression. Their quick onset of action, long-term clinical effects, and benign safety profiles have established them as neurologists' first line of choice for disease long-term management. Increasing regulatory approvals, favorable reimbursement in major markets, and expanding real-world evidence make them increasingly force the adoption of these products. As more biologics make their way to late-stage development, monoclonal antibodies will set the gold standard of care in MG management in the future.

Based on the distribution channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

Hospital pharmacies dominate the distribution channel segment for Myasthenia Gravis treatments due to the complex nature and high cost of biologics and immunomodulatory agents. Intravenous therapies such as IVIg, eculizumab, and emerging FcRn inhibitors are primarily administered in inpatient or specialized outpatient settings under close supervision. Hospital pharmacies ensure proper handling, dosing, and monitoring of these high-risk medications, which often require infusion centers and multidisciplinary oversight. Additionally, patients undergoing acute management or those presenting with myasthenic crises are directly treated in hospital environments, reinforcing the central role of institutional pharmacies. As biologics gain traction and more MG cases are managed in tertiary care centers, hospital pharmacies will continue to anchor the therapeutic distribution landscape.